Was used forparing MRI-determined residual tumor size and pathologic size. An unpaired t test with Welch correction was used to evaluate the presence of signi ance between high and low proliferation of Ki 7 as well as between HR and HR tumors. An F testpares populationsvariances. In this study we used an F test topare the range of axitinib tumor size discrepancy between groups. P 5 was considered signi ant. Results Tumor Subtypes and Biomarker Status millisecon TE millisecon ?ip angle 0 degre The HR stat histologic typ and morphologic types of mass matrix size 8, and FOV 8 cm. The scan time was 2 and nonmass lesions are listed in Table . Among the 4 analyzed seconds per acquisition. The sequence was repeated 6 times for dynamic acquisitio using precontrast sets and 2 postcontrast sets.
The earlier MRI studies from to were performed at T, and at that time the protocol was designed to have a high temporal resolution. When the study began using T instead of T in to meet the breast MRI guideli the protocol was changed to improve the spatial resolution by reducing the temporal resolution. The elapsed time between the last MRI and surgery was HER2 Inhibitors on average 6 days . patien 8 had HR tumo whereas 6 had HR tumors. HR tumors included 9 mass and nonmass lesion. HR tumors included 4 mass and only nonmass lesions . For histologic typ all tu-mors with lobular features were in the HR group. Of the 4 pa-tients with available Ki 7 informati 7 patients presented with mass lesions and presented with nonmass-like enhancement le-sions. Six of the nonmass lesions had lower Ki 7 expression and only showed high Ki 7 expression .
Clinical Breast Cancer April Aida Kuzucan Table parison Between HR-Positive and HR-Negative Breast Cancer Figure Triple-Negative Tumor With High Ki 7 Proliferation in Left Breast Baseline Magnetic Resonance Imaging Scan Before HR HR P Value Neoadjuvant Chemotherapy . Follow-pCR Rate 6 7 Up MRI During NAC pericardium Treatment. Last MRI Scan After the NAC Treatment waspleted. Lesion Type Followingplete Response was Indicated Mass lesion Nonmass lesion 6 2 2 by M and Conmed by Surgical Pathology Histologic Type A Pure ductal cancer Mixed ductal and lobular cancer 8// 6 6 6 Surgery Mastectomy Lumpectomy Excision 1/ / 6 3 Diagnosis True negative True positive False negative False positive / 6 4 2 7 5 B Size . Range Size 5 Mean C Abbreviations: HR hormone receptor; MRI magnetic resonance imaging.
Diagnostic Performance of MRI Table also shows theparison of the pCR ra surgical treat-me performance of MRI diagnos and size discrepancy between MRI and pathologic diagnosis for both HR and HR cancers. Overa 7 of the 4 patients were diagnosed with pCR ” without any remaining invasive cancer cells seen in the pathologic examination. In this coho 0 of patients with HR dis-ease achieved p which was much higher than the 4 in HR patients. However the difference was not statistically signi? D cant . MRI correctly diagnosed 6 of the 7 patients with pCR as C showing no suspicious enhanced le-sions . MRI had false-positive diagnos for which it showed lesion enhanceme but pathologic examination showed only ductal carcinoma in situ and hyperplasia. For the 4 patients with available Ki 7 informati of the 4 patients with low Ki 7 expression showed p whereas .